Protara Therapeutics Announces 2024 Annual Meeting of Stockholders
Ticker: TARA · Form: DEF 14A · Filed: Apr 26, 2024 · CIK: 1359931
| Field | Detail |
|---|---|
| Company | Protara Therapeutics, Inc. (TARA) |
| Form Type | DEF 14A |
| Filed Date | Apr 26, 2024 |
| Risk Level | low |
| Pages | 14 |
| Reading Time | 17 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Protara Therapeutics, Annual Meeting, Stockholders, Virtual Meeting, Proxy Statement
TL;DR
<b>Protara Therapeutics will host its 2024 Annual Meeting of Stockholders virtually on June 7, 2024.</b>
AI Summary
Protara Therapeutics, Inc. (TARA) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Protara Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on June 7, 2024. The meeting will be conducted virtually via live webcast at http://www.meetnow.global/MZKZMS6. Stockholders will have the same rights and opportunities to participate as in an in-person meeting. The company encourages attendance and participation, including submitting questions and voting. The proxy statement is filed under Schedule 14A, indicating it's a definitive proxy statement.
Why It Matters
For investors and stakeholders tracking Protara Therapeutics, Inc., this filing contains several important signals. This virtual format allows for broader participation from stockholders regardless of their physical location. The meeting serves as a platform for stockholders to engage with the company, ask questions, and vote on important matters.
Risk Assessment
Risk Level: low — Protara Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.
Analyst Insight
Stockholders should review the proxy materials to understand the agenda for the annual meeting and prepare any questions or votes.
Key Numbers
- June 7, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders.)
- 12:00 p.m. Eastern Time — Meeting Time (Time the virtual Annual Meeting will commence.)
Key Players & Entities
- Protara Therapeutics, Inc. (company) — Registrant and filer of the proxy statement.
- June 7, 2024 (date) — Date of the Annual Meeting of Stockholders.
- 2024 (date) — Year of the Annual Meeting of Stockholders.
- 345 Park Avenue South, Third Floor (location) — Business and mailing address of Protara Therapeutics.
- New York, NY 10010 (location) — Business and mailing address of Protara Therapeutics.
- http://www.meetnow.global/MZKZMS6 (url) — Webcast link for the virtual Annual Meeting.
FAQ
When did Protara Therapeutics, Inc. file this DEF 14A?
Protara Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Protara Therapeutics, Inc. (TARA).
Where can I read the original DEF 14A filing from Protara Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Protara Therapeutics, Inc..
What are the key takeaways from Protara Therapeutics, Inc.'s DEF 14A?
Protara Therapeutics, Inc. filed this DEF 14A on April 26, 2024. Key takeaways: Protara Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on June 7, 2024.. The meeting will be conducted virtually via live webcast at http://www.meetnow.global/MZKZMS6.. Stockholders will have the same rights and opportunities to participate as in an in-person meeting..
Is Protara Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, Protara Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.
What should investors do after reading Protara Therapeutics, Inc.'s DEF 14A?
Stockholders should review the proxy materials to understand the agenda for the annual meeting and prepare any questions or votes. The overall sentiment from this filing is neutral.
How does Protara Therapeutics, Inc. compare to its industry peers?
Protara Therapeutics operates in the biotechnology sector, focusing on developing therapies. Annual meetings are standard corporate governance events for publicly traded companies.
Are there regulatory concerns for Protara Therapeutics, Inc.?
This filing is a proxy statement (DEF 14A) made in accordance with Section 14(a) of the Securities Exchange Act of 1934, requiring disclosure of information for shareholder voting.
Industry Context
Protara Therapeutics operates in the biotechnology sector, focusing on developing therapies. Annual meetings are standard corporate governance events for publicly traded companies.
Regulatory Implications
This filing is a proxy statement (DEF 14A) made in accordance with Section 14(a) of the Securities Exchange Act of 1934, requiring disclosure of information for shareholder voting.
What Investors Should Do
- Review the proxy statement for details on meeting agenda items and voting procedures.
- Log in to the virtual meeting platform prior to the start time on June 7, 2024.
- Prepare any questions for management to submit during the virtual meeting.
Key Dates
- 2024-06-07: Annual Meeting of Stockholders — Key date for stockholder participation and voting.
Year-Over-Year Comparison
This is the initial filing for the 2024 Annual Meeting of Stockholders, following the standard proxy statement format.
Filing Stats: 4,274 words · 17 min read · ~14 pages · Grade level 12.1 · Accepted 2024-04-26 16:05:56
Filing Documents
- ea0204554-01.htm (DEF 14A) — 1822KB
- tprotara_logo.jpg (GRAPHIC) — 97KB
- tsign_mary.jpg (GRAPHIC) — 16KB
- tproxy_001.jpg (GRAPHIC) — 1550KB
- tproxy_002.jpg (GRAPHIC) — 1153KB
- 0001213900-24-036627.txt ( ) — 5702KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION   38 NON-EMPLOYEE DIRECTOR COMPENSATION   52
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT   5 4 TRANSACTIONS WITH RELATED PERSONS   56 HOUSEHOLDING OF PROXY MATERIALS   58 OTHER MATTERS   59 APPENDIX A — 2024 EQUITY INCENTIVE PLAN   A-1 APPENDIX B — 2024 EMPLOYEE STOCK PURCHASE PLAN   B-1 i Table of Contents PROTARA THERAPEUTICS, INC. 345 Park Avenue South, Third Floor New York, New York 10010 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on June 7, 2024 at 12:00 p.m. Eastern Time Our board of directors is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of Protara Therapeutics, Inc., a Delaware corporation, to be held virtually, via live webcast at http://www.meetnow.global/MZKZMS6 , originating from New York, New York, on Friday, June 7, 2024 at 12:00 p.m. Eastern Time, and any adjournment or postponement thereof. To provide a consistent and convenient experience to all stockholders regardless of location, the Annual Meeting will be held in a virtual meeting format only, via live webcast on the internet, with no physical in -person meeting. Stockholders virtually attending the Annual Meeting will be afforded the same rights and opportunities to participate as they would at an in -person meeting. For the Annual Meeting, we have elected to furnish our proxy materials, including this proxy statement and our Annual Report on Form 10 -K for the fiscal year ended December 31, 2023 (the “Annual Report”), to our stockholders primarily via the internet. On or about April 26, 2024, we expect to mail to our stockholders a Notice of Internet Availability of Proxy Materials (the “Notice”) that contains notice of the Annual Meeting and instructions on how to access our proxy materi